Heart failure drug for people with artificial heart valves
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a drug called sacubitril/valsartan to see if it helps people who have both a prosthetic heart valve and heart failure with a weak heart pump. The goal is to improve heart function and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a prosthetic (artificial) heart valve.
- You have been diagnosed with heart failure and your heart's pumping strength is low (ejection fraction 40% or less).
- You experience symptoms like shortness of breath or fatigue even with mild activity (NYHA class II to IV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called sacubitril-valsartan for people in rural Tanzania with heart failure and reduced pumping strength. It aims to see if switching to this drug can improve symptoms and outcomes.
This trial tests sacubitril/valsartan to help prevent heart weakness (cardiotoxicity) caused by breast cancer treatments like anthracyclines and/or anti-HER2 drugs. If you qualify, you may be offered this heart-protection medicine while your cancer is treated.
This study tests when to start two heart-protective medications (ARNI and SGLT2 inhibitors) after you've had surgery to fix a valve problem or blocked heart arteries. Researchers want to see if waiting a bit before starting these drugs helps your heart recover better.
This study tests a heart medication (sacubitril/valsartan) in young cancer survivors whose hearts were weakened by anthracycline chemotherapy but are not yet having heart failure symptoms. It aims to see if the drug can improve heart function and prevent future problems.
This trial tests if a combination medication (sacubitril/valsartan) can improve the heart's ability to relax and fill properly in people with heart failure and a very weak heart pump (ejection fraction less than 35%). It's for patients who are already on standard heart failure medicines.
This trial compares two blood-pressure and heart-failure medicines: sacubitril/valsartan versus ramipril, to see which improves heart pumping and heart structure over time. It’s aimed at people with ischemic (blocked-artery) heart failure with mid-range ejection fraction and ongoing symptoms.
Hear when a new Sacubitril/Valsartan trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.